Low-dose outpatient chemobiotherapy with temozolomide, granulocyte- macrophage colony stimulating factor, interferon-α2b, and recombinant interleukin-2 for the treatment of metastatic melanoma

Journal of Clinical Oncology

Volumn 23, Issue 35, 2005, Pages 8992-9000

  Weber, Robert W ^a   O'Day, Steven ^a   Rose, Madalene ^a   Deck, Regina ^a   Ames, Patricia ^a   Good, James ^a   Meyer, John ^a   Allen, Robert ^a   Trautvetter, Sharon ^a   Timmerman, Molly ^a   Cruickshank, Scott ^a   Cook, Mary ^a   Gonzalez, Rene ^a   Spitler, Lynn E ^a  

^a Saint Francis Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; DYSPEPSIA; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HUMAN; INJECTION SITE REACTION; MALE; MELANOMA; METASTASIS; MOOD CHANGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SWEAT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; AMBULATORY CARE; CANCER STAGING; DISEASE COURSE; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644805723     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.5791     Document Type: Article

References (36)

1. de Gast GC, Klumpen HJ, Vyth-Dreese FA, et al: Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6:1267-1272, 2000
2. Groenewegen G, Bloem A, de Gast GC: Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: Outpatient treatment with dacarbazine, granulo-cyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha. Cancer Immunol Immunother 51:630-636, 2002
3. de Gast GC, Batchelor D, Kersten MJ, et al: Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma. Br J Cancer 88:175-180, 2003
4. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
5. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
6. O'Day SJ, Boasberg PD, Piro L, et al: Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 8:2775-2781, 2002
7. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
8. Cancer Staging Manual AJCC (ed 6). New York, NY, Springer, 2002
9. Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793, 2000
10. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma: IV, Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1:126-134, 1983
11. Brand CU, Ellwanger U, Stroebel W, et al: Prolonged survival of 2 years or longer for patients with disseminated melanoma: An analysis of related prognostic factors. Cancer 79:2345-2353, 1997
12. Paul MJ, Summers Y, Calvert AH, et al: Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 12:175-178, 2002
13. Bafaloukos D, Gogas H, Georgoulias V, et al: Temozolomide in combination with docetaxel in patients with advanced melanoma: A phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 20:420-425, 2002
14. Atkins MB, Gollob JA, Sosman JA, et al: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 8:3075-3081, 2002
15. Ostermann S, Csajka C, Buclin T, et al: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728-3736, 2004
16. Patel M, McCully C, Godwin K, et al: Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61:203-207, 2003
17. Agarwala SS, Kirkwood JM, Gore M, et al: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 22:2101-2107, 2004
18. Avril MF, Aamdal S, Grob JJ, et al: Fotemustine compared with dacarbazine in patients with disseminated malignant mela-noma: A phase III study. J Clin Oncol 22:1118-1125, 2004
19. Chapman PB, Einhorn LH, Meyers ML, et al: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745-2751, 1999
20. Middleton MR, Grob JJ, Aaronson N, et al: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158-166, 2000
21. Atkins MB, Lotze MT, Dutcher JP, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999
22. Sparano JA, Fisher RI, Sunderland M, et al: Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969-1977, 1993
23. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
24. Eton O, Legha SS, Bedikian AY, et al: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. J Clin Oncol 20:2045-2052, 2002
25. Atkins MB: A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 21:2847a, 2003
26. Keilholz U: Dacarbazine, cisplatin and IFN-a2b with or without IL-2 in advanced melanoma: Final analysis of EORTC randomized phase III trial 18951. Proc Am Soc Clin Oncol 21:2848a, 2003
27. Del Vecchio MM, Bajetta E, Vitali M, et al: Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma patients (pts). Proc Am Soc Clin Oncol 21:2849a, 2003
28. Schuchter LM: Overview of randomized biochemotherapy studies. Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003
29. Hwu WJ, Raizer J, Panageas KS, et al: Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol 2:634-635, 2001
30. Hwu WJ, Krown SE, Menell JH, et al: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21:3351-3356, 2003
31. Hwu WJ, Krown SE, Panageas KS, et al: Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial. J Clin Oncol 20:2610-2615, 2002
32. Thompson JA, Gold PJ, Markowitz DR, et al: Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3:S29-S34, 1997 (suppl 1)
33. Thompson JA, Gold PJ, Fefer A: Out-patient chemoimmunotherapy for the treatment of metastatic melanorna. Semin Oncol 24:S44-S48, 1997
34. Celgene Announces Plans to Stop Phase III Trials in Melanoma Due to Lack of Efficacy. http://ir.celgene.com/phoenix.zhtml?c=111960&p =irol-newsArticle&ID=520356&highlight= revlimid, 2004
35. Maxim Pharmaceutical Phase 3 Trial for Advanced Malignant Melanoma Fails to Meet Primary Endpoint. http://investors.maxim. com/releaseDetail.cfm? releaseID=143390, 2004
36. Genta Announces Updated Results from its Phase 3 Trial of Genasense for Advanced Melanoma. http://www.genta.com/Genta/InvestorRelation/2004/ press_20040607.html, 2004